Philip P. Gutry's Insider Trades & SAST Disclosures
Philip P. Gutry's most recent trade in Graphite Bio Inc was a trade of 5,000 Common Stock done at an average price of $4.0 . Disclosure was reported to the exchange on April 11, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Philip P. Gutry.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Graphite Bio Inc | Philip P. Gutry | CHIEF BUSINESS OFFICER | Purchase of securities on an exchange or from another person at price $ 4.01 per share. | 11 Apr 2022 | 5,000 | 299,941 | - | 4.0 | 20,050 | Common Stock |
| Avalo Therapeutics Inc | Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 4,718 | 4,718 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 3,142 | 3,142 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 3,783 | 3,783 | - | - | Stock Option (Right to Buy) | |
| Graphite Bio Inc | Philip P. Gutry | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 162,410 | 162,410 | - | - | Stock Option (right to buy) | |
| Graphite Bio Inc | Philip P. Gutry | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 13 Jan 2021 | 91,406 | 281,962 | - | 0.3 | 27,422 | Common Stock |
| Graphite Bio Inc | Philip P. Gutry | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 91,406 | 91,406 | - | - | Stock Option (right to buy) | |
| Graphite Bio Inc | Philip P. Gutry | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 91,406 | 0 | - | - | Stock Option (right to buy) | |
| Graphite Bio Inc | Philip P. Gutry | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 69,604 | 69,604 | - | - | Stock Option (right to buy) | |
| Graphite Bio Inc | Philip P. Gutry | CHIEF BUSINESS OFFICER | 13 Jan 2021 | 19,763 | 0 | - | - | Series B Preferred Stock | ||
| Graphite Bio Inc | Philip P. Gutry | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 19,763 | 19,763 | - | - | Series B Preferred Stock | |
| Graphite Bio Inc | Philip P. Gutry | CHIEF BUSINESS OFFICER | 13 Jan 2021 | 8,126 | 293,471 | - | - | Common Stock | ||
| Graphite Bio Inc | Philip P. Gutry | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 3,383 | 159,027 | - | - | Stock Option (right to buy) | |
| Graphite Bio Inc | Philip P. Gutry | CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 13 Jan 2021 | 3,383 | 285,345 | - | 6.1 | 20,670 | Common Stock |
| Avalo Therapeutics Inc | Philip Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 4,516 | 4,516 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Philip Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 3,812 | 3,812 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Philip Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Philip Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2020 | 4,310 | 4,310 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges